A research recent featured in the Journal of AIDS and HIV Research showed the potential of Low-Dose Naltrexone (LDN) in stabilizing CD4 counts among untreated HIV+ individuals and amplifying CD4 count increments when used alongside antiretroviral therapy. This breakthrough offers promising prospects for advancing HIV management strategies.
Compounding of LDN capsules
In the realm of HIV care, compounding pharmacists play an important role in customizing LDN capsules for patients, recognizing the critical role of excipients in pharmaceutical formulations. Originally perceived as inert, excipients now act as active agents, influencing various factors important for the effectiveness of dosage forms. The meticulous selection of excipients ensures optimal bioavailability, solubility, stability, precise dosing, and sensory enhancements, proving indispensable in tailoring LDN capsules for personalized HIV care.
DiluCap: The right excipient for your capsules
Fagron offers an innovative range of excipients designed to facilitate compounding pharmacists in formulating capsules with assured final characteristics. The DiluCap range, developed following the Biopharmaceutical Classification System (BCS System), aligns with scientific criteria correlating drug dissolution and bioavailability. Rigorously tested, these excipients match each API, ensuring THE RIGHT EXCIPIENT for optimal performance.
Advantages of choosing to standardize your capsules’ excipients with DiluCap include:
- Avoidance of segregation between API and other formulation components.
- Preservation of API stability.
- Dose accuracy, as they facilitate the distribution of particles from the API.
- Modulation of the solubility and bioavailability of API.
- Good flux properties.
- Absence of allergens such as lactose, gluten, soy, and others.
- Proven functionality.
- No need for other adjuvants.
- Developed based on the biopharmaceutical classification.
- Physiologically inert.
- Reduction of process time and the number of items in stock.
- Batch-to-batch reproducibility.
You can read more about DiluCap SLD, DiluCap PSD, DiluCap Hygro, DiluCap Antioxi, DiluCap SR & DiluCap OD here.
The best choice
Considering Naltrexone’s hydrophobic nature and poor solubility, addressing these barriers becomes necessary when formulating patient-specific LDN at low doses. The DiluCap PSD or DiluCap SR excipients emerge as preferred choices due to their ability to overcome these challenges. DiluCap PSD aids Naltrexone’s disintegration and dissolution, while DiluCap SR moderates release rates, facilitating slow-release formulations, essential in preventing adverse effects associated with rapid plasma peaks.
The incorporation of sophisticated excipients, such as the ones offered by Fagron, represents an evolution in oral dosage formulation science. These advancements provide healthcare professionals with the capability to develop customized formulations, thereby improving treatment effectiveness and patient outcomes. As ongoing research uncovers progressive strategies in HIV and AIDS management, the future shows promise for the development of more effective and personalized approaches to ensure treatment success.
